Mounjaro weight management banner

She has tried multiple times,
yet her attempts at losing weight and maintaining it have been unsuccessful

She is worried about her excess weight and risk of obesity-related complications*

She is starting to feel the physical and psychological consequences of excess weight in her daily life

See how people like Anjali may achieve
their weight goals with Mounjaro®

Get started

*Hypothetical patient profile

Mounjaro is the first and only GIP and GLP-1 receptor agonist approved for weight management that may help patients living with obesity achieve their weight goals.1-3,*

The role of GIP and GLP-1 receptors Find out more Mounjaro’s effects on the body See how it works

The role of GIP and GLP-1 receptors

Find out more
  • GIP and GLP-1 receptors are present in many body areas, including brain regions that regulate appetite1,a
  • GIP receptors are present in adipose tissue and help regulate fat storage1,4
  • GLP-1 regulates gastric emptying and feelings of satiety in the brain1,8
Brain

Brain

GIP activity8,b

Reduced food intake

GLP-1 activity6,8

Reduced food intake

Increased satiety

Adipose tissue

Subcutaneous
white adipose tissue

GIP activity4,8

Increased insulin sensitivity

Pancreas

Pancreas

GIP activity9

Increased insulin secretion

Increased glucagon in a glucose-dependent way

GLP-1 activity9

Increased insulin secretion

Reduced glucagon secretion

Stomach

Stomach

GLP-1 activity7

Delayed gastric emptying

aAreas of the body such as the pancreatic α and β endocrine cells, heart, vasculature, immune cells (leukocytes), gut, and kidney.1
bDemonstrated in preclinical trials.8
Mounjaro’s effects on the body
See how it works

Mounjaro may have several effects on the body that help
support weight reduction in patients living with obesity1,10:

Human body illustration

Mounjaro is the first and only GIP and GLP-1 receptor agonist approved for weight management that may help patients living with obesity achieve their weight goals.1-3,*

SURMOUNT-1 study design See the data CHANGE IN BODY WEIGHT See the data CHANGE IN BODY COMPOSITION See the data IMPROVEMENTS IN KEY CARDIOMETABOLIC PARAMETERS See the data SAFETY OVERVIEW See the data


Safety data
See details
Safety data chart 1 Safety data chart 2 Safety data chart 3 Safety data chart 4 Safety overview chart
Therapeutic Indication1

Type 2 diabetes mellitus

MOUNJARO® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications

• in addition to other medicinal products for the treatment of diabetes.

Weight management

MOUNJARO® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of:

• ≥ 30 kg/m2 (obesity) or

• ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).

Reference: 1. Jastreboff AM, et al. N Engl J Med. 2022;387(3):205–16 (+Suppl. Appendix). 2. Tirzepatide (Mounjaro) India Prescribing Information | Updated March 2025. 3. Magkos F, et al. Cell Metab. 2016;23(4):591–601. 4. Jastreboff AM. Presentation. 58th EASD Congress Sweden 2022 [21 December 2023]. Available from URL: https://www.practiceupdate.com/content/easd-2022-substantial-weight-reduction-with-tirzepatide-produces-multiple-beneficial-metabolic-effects/142614 . 5. Samms RJ, et al. Trends Endocrinol Metab. 2020;31(6):410–21. 6. Aronne LJ, et al. J Obes Facts 2023;16(Suppl1):1–351. Abstract Session AD09.02.
Disclaimer:

This material (including any link) is intended solely for the use of the recipient(s) and may contain confidential information. Any unauthorized review, use, disclosure, copying, or distribution is strictly prohibited. If you are not the intended recipient, please notify the sender immediately and destroy all copies of the material. The information provided in this section is intended solely for the use of registered medical practitioner. This material is being provided to healthcare professionals for their guidance and use. Nothing on this website/microsite/material should be construed as giving medical advice or making recommendations regarding any health-related decision or action.

Mounjaro®, KwikPen® and Lilly are registered trademarks of Eli Lilly and Company. To be sold by retail under prescription of Endocrinologist or Internal Medicine Specialists only.

For adverse events and safety reporting, please reach out to: mailbox_in-gps@lilly.com

For any additional information related to Lilly products, please reach out to: queries_in-medinfo@lilly.com.

For further Information about Lilly and Lilly products please contact us at the below address: Plot 92, Sector 32 Gurgaon, Haryana, 122001 India Ph.: +91-124-4753000/01 | www.lilly.com/in

PP-TR-IN-1199 | 28 Jan‘26   ©2026| Eli Lilly and Company. All rights reserved.
Therapeutic Indication1

Type 2 diabetes mellitus

MOUNJARO® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications

• in addition to other medicinal products for the treatment of diabetes.

Weight management

MOUNJARO® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of

• ≥ 30 kg/m2 (obesity) or

• ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).

Reference: 1. Jastreboff AM, et al. N Engl J Med. 2022;387(3):205–16 (+Suppl. Appendix). 2. Tirzepatide (Mounjaro) India Prescribing Information | Updated March 2025. 3. Magkos F, et al. Cell Metab. 2016;23(4):591–601. 4. Jastreboff AM. Presentation. 58th EASD Congress Sweden 2022 [21 December 2023]. Available from URL: https://www.practiceupdate.com/content/easd-2022-substantial-weight-reduction-with-tirzepatide-produces-multiple-beneficial-metabolic-effects/142614 . 5. Samms RJ, et al. Trends Endocrinol Metab. 2020;31(6):410–21. 6. Aronne LJ, et al. J Obes Facts 2023;16(Suppl1):1–351. Abstract Session AD09.02.
Disclaimer:

This material (including any link) is intended solely for the use of the recipient(s) and may contain confidential information. Any unauthorized review, use, disclosure, copying, or distribution is strictly prohibited. If you are not the intended recipient, please notify the sender immediately and destroy all copies of the material. The information provided in this section is intended solely for the use of registered medical practitioner. This material is being provided to healthcare professionals for their guidance and use. Nothing on this website/microsite/material should be construed as giving medical advice or making recommendations regarding any health-related decision or action.

Mounjaro®, KwikPen® and Lilly are registered trademarks of Eli Lilly and Company. To be sold by retail under prescription of Endocrinologist or Internal Medicine Specialists only.

For adverse events and safety reporting, please reach out to: mailbox_in-gps@lilly.com

For any additional information related to Lilly products, please reach out to: queries_in-medinfo@lilly.com.

For further Information about Lilly and Lilly products please contact us at the below address: Plot 92, Sector 32 Gurgaon, Haryana, 122001 India Ph.: +91-124-4753000/01 | www.lilly.com/in

PP-TR-IN-1199 | 2 April‘26   ©2026| Eli Lilly and Company. All rights reserved.